Is Arbutus Biopharma Corp (ABUS) Worthy of Your Portfolio?

Page 1 of 2

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a greater amount of their resources in small-cap stocks than big brokerage houses, and this is often where they generate their outperformance, which is why we pay particular attention to their best ideas in this space..

In this article, we’ll take a look at the latest hedge fund activity, surrounding Arbutus Biopharma Corp (NASDAQ:ABUS). Overall, the stock registered a decline in popularity among the funds in our database during the third quarter, and 11 funds reported long positions in ABUS as of the end of September. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Cellectis SA (ADR) (NASDAQ:CLLS), FIRST FINANCIAL NORTHWEST, INC. (NASDAQ:FFNW), and MVC Capital, Inc. (NYSE:MVC) to gather more data points.

Follow Arbutus Biopharma Corp (NASDAQ:ABUS)

We follow over 700 hedge funds and other institutional investors and by analyzing their quarterly 13F filings, we identify stocks that they are collectively bullish on and develop investment strategies based on this data. One strategy that outperformed the market over the last year involves selecting the 100 best-performing funds and identifying the 30 mid-cap stocks that they are collectively most bullish on. Over the past year, this strategy generated returns of 18%, topping the 8% gain registered by S&P 500 ETFs. We launched this strategy 2.5 years ago and it returned more than 39% since then, vs. 22% gain registered by the S&P 500 ETFs.

test, cancer, researcher, research, dna, bio, clean, modern, chemistry, human, white, medical, sample, pipette, life, culture, laboratory, biotechnology, genetic, disease,

science photo/

With all of this in mind, let’s view the recent action regarding Arbutus Biopharma Corp (NASDAQ:ABUS).

Hedge fund activity in Arbutus Biopharma Corp (NASDAQ:ABUS)

At the end of the third quarter, a total of 11 of the hedge funds tracked by Insider Monkey were bullish on this stock, down by 15% from one quarter earlier. By comparison, nine hedge funds held shares or bullish call options in ABUS heading into this year. So, let’s check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

ABUS Chart

Of the funds tracked by Insider Monkey, Daniel Gold’s QVT Financial has the number one position in Arbutus Biopharma Corp (NASDAQ:ABUS), worth close to $55.1 million, amounting to 2.1% of its total 13F portfolio. Coming in second is Richard Gerson and Navroz D. Udwadia of Falcon Edge Capital, with a $9 million position; the fund has 0.7% of its 13F portfolio invested in the stock. Some other members of the smart money that hold long positions include Arthur B Cohen and Joseph Healey’s Healthcor Management LP, D E Shaw, one of the biggest hedge funds in the world, and Steven Boyd’s Armistice Capital. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2